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Phylogenetic analysis of metastatic progression
in breast cancer using somatic mutations and copy
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Several studies using genome-wide molecular techniques have reported various degrees of
genetic heterogeneity between primary tumours and their distant metastases. However, it has
been difﬁcult to discern patterns of dissemination owing to the limited number of patients
and available metastases. Here, we use phylogenetic techniques on data generated using
whole-exome sequencing and copy number proﬁling of primary and multiple-matched
metastatic tumours from ten autopsied patients to infer the evolutionary history of breast
cancer progression. We observed two modes of disease progression. In some patients, all
distant metastases cluster on a branch separate from their primary lesion. Clonal frequency
analyses of somatic mutations show that the metastases have a monoclonal origin and
descend from a common ‘metastatic precursor’. Alternatively, multiple metastatic lesions are
seeded from different clones present within the primary tumour. We further show that
a metastasis can be horizontally cross-seeded. These ﬁndings provide insights into breast
cancer dissemination.
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C
ancer-related mortality is almost always due to metastatic
dissemination of the primary disease. While research
continues to unravel the molecular underpinnings of the
metastatic cascade, it is increasingly recognized that proﬁling of
advanced disease could help elucidate such biological phenomena
as distant recurrence and the emergence of de novo resistance
to therapy.
A handful of studies using genome-wide molecular techniques
have begun to explore the clonal relationships between
primary and matched metastatic tumours in diverse types of
neoplasia including pancreatic1,2, clear-cell renal cell3, high-grade
serous ovarian4–6 and prostate cancer7,8. Despite the small cohort
sizes and, too often, a limited number of matched metastases for
each patient, these pioneering efforts brought forth thought-
provoking ﬁndings such as the ﬁrst quantitative model of cancer
progression from onset of the founder mutation to metastatic
dissemination2, the occurrence of organ speciﬁc lineages1,
monoclonal3–8, as well as its counterpart, polyclonal seeding7,8,
horizontal cross-seeding between distant metastases6,8, and
ﬁnally homing of metastatic cells to the primary tumour bed7.
While yet other studies continue to highlight the potential of
genomic analyses from small cohort sizes to decipher the
origins of intra-tumour heterogeneity and its contribution to
metastatic dissemination9,10, in-depth knowledge is currently
lacking for breast cancer. Several studies have tackled this
issue11–19. However, while early attempts were constrained
by the development of high throughput genomic techniques,
more recent endeavours were, on the other hand, limited in
scope by the availability of multiple-matched metastases.
Noteworthy exceptions are the work of Juric et al.15
and Murtaza et al.16, both n-of-1 fast autopsy studies,
where the authors uncovered the mechanisms of resistance
to a PI3K-inhibitor and lapatinib, respectively. Despite this,
it remains difﬁcult to discern any pattern of metastatic
progression due to the small number of patients.
To further investigate breast cancer progression, we applied
phylogenetic techniques on data generated using whole-exome
sequencing, custom ultra-deep resequencing and copy number
proﬁling. The primary tumours and their associated metastases
were obtained from ten autopsied patients. We observed two
modes of metastatic progression. In the majority of cases,
all distant metastases cluster on a branch separate from their
primary lesion. Clonal frequency analyses of somatic mutations
show that the metastases have a monoclonal origin and
descend from a common ‘metastatic precursor’. Alternatively,
the primary tumour is clustered alongside metastases with
early branches leading to distant organs. Finally, we show
that a distant metastasis can be horizontally cross-seeded
conﬁrming previous results observed in other types of neoplastic
disorders6,8 and lending further support to the self-seeding
hypothesis20.
Results
Characteristics of patients and samples. We reviewed the
database of the institutional autopsy programme of the second
Department of Pathology at Semmelweis University. From
50 deceased metastatic breast cancer patients, whose corpses
underwent autopsy between 2001 and 2012, ten patients for
whom 41mg double-stranded DNA from the primary breast
tumour, a non-cancerous tissue as germline reference, and
at least one metastatic sample was available, were selected. Eight
patients were diagnosed with early stage disease among whom,
one was diagnosed with a single liver metastasis (5/87).
Three patients (3/92, 5/87 and 6/91) received neoadjuvant
chemotherapy before surgery while the remaining ﬁve patients
(4/71, 7/67, 8/82, 9/68 and 10/80) were treated with breast
surgery followed by adjuvant systemic therapy according to
standard of care. The remaining two patients (1/69 and 2/57)
were diagnosed with de novo metastatic disease and deceased
before receiving any systemic or surgical treatment. The
patient clinico-pathological characteristics are provided in
Supplementary Data 1 while the clinical history and autopsy
ﬁndings are detailed in Supplementary Notes 1–10 corresponding
to patient 1/69 to 10/80. The lesions proﬁled are described in
Supplementary Data 2. All samples from the de novo metastatic
patients were collected post-mortem while, for the remaining
patients, the primary tumours were collected at surgery and the
distant metastases, in addition to one case of local recurrence,
were collected at autopsy. On average, three distant metastatic
lesions were proﬁled per patient.
Indexing of somatic mutations and copy number aberrations.
We used whole-exome sequencing to index somatic mutations
from 51 samples (median coverage 40±18 ) followed by
orthogonal validation using Sequenom MassARRAY to exclude
false positive calls and targeted amplicon ultra-deep sequencing
(median coverage 11,390±5,646 ) to obtain accurate variant
allele frequencies (VAFs). The list of single nucleotide variants
(SNVs) from each patient is provided in Supplementary Data 3.
We supplemented this with high density single nucleotide
polymorphism (SNP) arrays to characterize the underlying
copy number aberrations (CNAs) in 64 matched samples
(Supplementary Data 4). We further devised a multiple tier
system to ascribe a conﬁdence level to each indexed mutation.
Between 27 and 305 non-synonymous SNVs per patient
were successfully validated up to tier-3 level and after applying
deﬁned quality criteria, a total of 56 samples with either CNA or
sequencing data remained for downstream analysis.
Phylogenetic reconstruction of metastatic progression.
Metastases are clonally related and originate from cells
disseminated at various stages of the disease. Thus, they inherit
varying fractions of genomic alterations from their parental
lineage, followed by acquisition of private alterations. Provided
the genomic alterations under investigation are fully clonal,
phylogenetic inference can be used to investigate lineage tracing
of metastases within a patient. Therefore, we used a maximum
parsimony criterion to infer the sequence of genomic alterations
occurring during metastatic progression. Figure 1a–f illustrates
the results obtained in patient 2/57. Whenever the two
phylogenies obtained from SNVs and CNAs were consistent,
these were graphically represented as a combined tree. In the case
of SNV-based phylogenies containing unresolved nodes, so called
soft polytomies, we used the corresponding tree generated from
CNAs as the correct phylogeny on account of the greater number
of aberrations from SNP arrays, allowing for a unique solution
to tree reconstruction.
The combined use of SNVs and CNAs demonstrated the
presence of reversions, that is, SNVs predicted as present in
a sample from the ancestral state reconstruction but were not
detected in the particular sample. For the predicted reversions, we
excluded the possibility that these were due to false negative
calls attributable to inadequate sequencing coverage depth or
the occurrence of the mutations at subclonal cell frequencies
based on power calculations described in Carter et al.21
(Supplementary Fig. 1). Instead, Fig. 2a–i shows two clusters
of reversions in the metastasis to the pylorus from patient 8/82,
which can be attributed to loss of heterozygosity at chromosome
1p and 17p in that lesion. We further encountered a similar
phenomenon in patient 9/68 (Supplementary Fig. 2) where the
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change in copy number status of chromosome 19p can be
tracked across the phylogenetic tree and explains the reversion
of the mutation in F2RL3. The occurrence of reversions has
seldom been acknowledged in the literature and despite
growing interest in the inference of phylogenies from single or
multiple samples, several approaches have falsely relied on
the hypothesis of ‘no back mutation’. Therefore, these examples
serve as cautionary tale when performing such analysis without
properly matched sequencing and CNA data.
Disease dissemination via a metastatic precursor. We applied
the same workﬂow to all patients for whom both SNV and
CNA data were available. We refer to ‘early’ and ‘late’ alterations
when occurring in the trunk or the branches of the phylogenetic
trees, respectively. A representative combined phylogeny for
patient 7/67 is illustrated in Fig. 3. This patient was diagnosed
at the age of 54 with an ER-/PgR-/HER2-primary breast cancer.
She deceased 3 years later despite surgery and several lines of
systemic treatments. All the distant metastases clustered together
and descended from what we refer to as the ‘metastatic
precursor’. We computed the clonal frequencies from the VAFs,
the global cancer cell fraction (CCF) and the copy number states
for each SNV. These are represented as pairwise comparisons
of samples (Fig. 3d). Similarly, the phylogenies of patients with
early breast cancer disease (4/71, 8/82, 9/68 and 10/80), and
the one from patient 5/87 with a single liver metastasis at
initial diagnosis, further conﬁrmed the case of patient 7/67
(Fig. 5a; Supplementary Figs 4 and 5). Distant metastases
probably arose via a seeding event to an initial ‘metastatic
precursor’ from the primary tumour and in absence of the latter,
removed at surgery, the source of further dissemination
to additional organs occurred by metastasis-to-metastasis
disseminations. Our observation suggests that for breast cancer
patients diagnosed at an early stage and undergoing curative
intent surgery, who represent the majority of patients, cascading
disseminations from metastases appears to be a major route
of tumour progression.
For seven patients from our cohort, multiple samples from
the primary tumour were available (3/92, 4/71, 5/87, 6/91, 8/82,
9/68 and 10/80). In two cases, a particular region of the primary
tumour was more genetically related to the distant metastases.
For patient 3/92, the phylogenetic tree based on CNAs
(Supplementary Fig. 9) show that the primary tumour sample
(P3) was clustered alongside the metastases to the liver (M2) and
pancreatic lymph node (M3) while for patient 6/91, the tree
inferred from tier-3 SNVs (Supplementary Fig. 7) shows that
the primary tumour sample (P3) is clustered alongside the
metastases to the brain (M1) and liver (M2). Apart from these
two exceptions, in all the other patients, the different samples
from the primary tumour were clustered together separate
from their associated distant metastases (Fig. 2; Supplementary
Figs 7 and 9).
Multiple seeding events from the primary tumour.
A contrasting clinical and biological condition to the dissemination
via a ‘metastatic precursor’ is illustrated by the case of patient
2/57 (Fig. 4). This patient was a BRCA1 germline mutation
carrier diagnosed at the age of 38 with an ER-/PgR-/HER2-
metastatic breast cancer. She did not receive any systemic
treatment and deceased 1 month after initial diagnosis. Analysis
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Figure 1 | Phylogenetic inference from SNVs and CNAs. Fully clonal somatic CNAs of chromosome 3 for (a) the primary tumour, (b) the liver and
(c) the ovarian metastases of patient 2/57. The tracks are in descending order, the B Allele Frequency (BAF), integer copy number (CN) state and
log2 ratios. The phylogenetic reconstruction is displayed in d, where arrows indicate aberrations with annotations besides detailing coordinates and
event type. Convergent evolution is exempliﬁed by the focal ampliﬁcation of region d in a,b but a broad gain of c–e in c, in all three cases leading to copy-
neutral loss of heterozygosity of region d. The CNAs are colour coded with ‘early’ events in blue, ‘late’ events in orange, and diploid regions not contributing
to the phylogenetic tree in black. (e) Concordant phylogeny obtained from tier-3 SNVs and (f) ancestral state reconstruction for the same samples. The
scale bars in (d,e) represent one CNA and 10 SNVs, respectively.
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of her primary tumour (P) and two distant metastases revealed
two independent seeding events from the primary leading
to the ovarian (M3) and to the liver (M1) secondary lesions,
respectively (Fig. 1d,e). The phylogenetic reconstruction from
the CNA proﬁle of the metastasis to the adrenal gland (M2)
revealed that this lesion originated from a precursor shared
with the liver metastasis (Fig. 4b). However, the adrenal gland
lesion displayed both SNVs acquired ‘late’ in the evolutionary
history of the clade composed of the primary tumour and
liver metastasis as well as SNVs private to the ovarian metastasis.
Pairwise comparisons of the clonal frequencies of tier-4
SNVs showed that those private to the primary tumour and
liver metastasis clade (segment 4) were also present at full
clonal frequencies in the adrenal gland metastasis (Fig. 4c) in
agreement with the phylogeny inferred from the CNA proﬁles.
The ‘late’ SNVs private to the ovarian metastasis (segment 2)
were observed at subclonal frequencies in the adrenal gland
metastasis. We resequenced M2 and obtained similar results
(Supplementary Fig. 3). Our results imply that circulating
metastatic cells, disseminated by the ovarian metastasis,
horizontally cross-seeded the already metastatic adrenal gland
and conﬁrm previous observations in ovarian6 and prostate8
cancers further lending support to the hypothesis of tumour
self-seeding20.
In the additional advanced stage breast cancer patient
(1/69) who was de novo metastatic and died in the weeks
following her diagnosis without receiving any systemic treatment,
the primary sample was also found clustered alongside
distant metastases (Fig. 5b; Supplementary Fig. 6). We observed
a similar early seeding to distant organs (primary to pleura in
1/69 and primary to ovarium in 2/57) followed by subsequent
late seeding events to additional organs from either the primary
lesion (primary to aorta in 1/69 and primary to liver in 2/57)
or from already established metastases (mediastinal soft tissue
to mediastinal lymph node or vice versa in 1/69 and liver to
adrenal gland or vice versa in 2/57).
Contralateral breast tumours originate from primary tumours.
Two patients from our series were diagnosed with a metachronous
contralateral breast tumour. Patient 6/91, 1 year and 10/80,
10 years after initial diagnosis. In patient 6/91, the phylogenetic
reconstruction based on tier-3 SNVs showed that the
contralateral left tumour (M3) was the earliest branching but
shared a substantial fraction of the truncal SNVs (Supplementary
Fig. 7). This contrasts with the case of patient 10/80 where
the CNA proﬁles show that the contralateral left tumour (M1)
originated from a daughter lesion shared with the liver metastases
(M2 and M3) (Supplementary Fig. 9). Nonetheless, both cases
conﬁrm the clonal relatedness of the contralateral tumour with
the initially diagnosed breast cancer. Together with recent
reports22,23, this calls into question the current practice of
considering metachronous contralateral tumours as second
primary cancers. Since treatment strategies offered to patients
KI
AA
15
30
C4
or
f1
4
O
DZ
2
O
DZ
2
AD
AM
22
TM
EM
13
0
EH
BP
1L
1
D
CA
F1
1
CL
SP
N
PL
XD
C1
SL
C3
9A
1
IQ
GA
P3
CF
H
PX
D
N
M
YO
7B
PI
K3
CA
KC
NI
P4
PC
DH
7
N
FX
L1
BT
N
L8
H
IS
T1
H4
C
KI
AA
19
19
AE
BP
1
ZN
F7
13
N
AT
1
N
CO
A2
ZN
F3
2
G
AB
2
TT
C3
6
FL
I1
ER
BB
3
E2
F7
SL
C6
A1
5
D
CT C1
5o
rf2
7
PE
X1
1A
CD
H1
R
N
F4
3
SM
CH
D1
PI
K3
C3
G
RL
F1
N
LR
P7
AP
O
BE
C3
B
VP
S1
3D
ZN
F3
62
SL
C4
A1
AP
PS
M
E4
M
Y O
7B
SN
ED
1
KA
LR
N
PA
R
M
1
SL
C1
0A
7
TR
PC
7
SL
IT
3
H
IS
T1
H1
C
AK
D
1
AK
D
1
EP
H
X2
R
AB
11
FI
P1
AB
R
A
EI
F2
C2
TO
N
SL
TM
EM
8B
H
KD
C1
KI
AA
12
74
EC
D
CA
SP
7
PR
G
2
PA
AF
1
LO
H1
2C
R1
LR
P1
LR
P1
G
NS
SE
TD
1B
AD
CY
4
W
D
R
24
IF
T1
40
XY
LT
1
PR
RT
2
C1
6o
rf5
3
C1
6o
rf5
3
TS
R1
AA
R
SD
1
IF
I3
5
ET
V4
M
YC
BP
AP
ZN
F3
0
RT
N
2
C1
9o
rf1
8
ZN
FX
1
PP
D
PF
AP
EX
2
SL
C2
5A
43
F8 DN
AL
I1
UB
N2
RY
R
3
ZP
BP
2
G
NL
2
ET
V3
L
FC
RL
5
O
R6
K2
CO
PA
SE
LE
KI
FA
P3
M
Y O
C
CE
P3
50
KI
AA
16
14
H
M
CN
1
EX
O
C8
CN
ST
CN
ST
ZA
P7
0
LC
T
H
OX
D
9
AL
S2
CR
4
CC
DC
10
8
CC
DC
10
8
IT
PR
1
ZN
F5
02
AL
S2
CL
R
PL
29
D
N
AH
1
N
IS
CH
AB
TB
1
TF AB
CC
5
M
AS
P1
ZF
YV
E2
8
CC
DC
96
EX
O
C1
N
FK
B1
KI
AA
11
09
AD
AM
TS
16
R
G
NE
F
CM
YA
5
PC
DH
B1
FB
XO
38
PD
LI
M
7
H
IV
EP
1
TS
PY
L1
FR
M
D
1
EI
F2
AK
1
KD
EL
R
2
IK
ZF
1
FG
L2
SY
PL
1
CA
LB
1
IF
N
A7
SV
IL
AR
ID
5B
LD
B1
LD
B1
C1
0o
rf1
22
IP
O
7
O
R4
C1
5
TR
M
T1
12
IG
HM
BP
2
EN
D
O
D1
CA
SP
1
PD
E3
A
IF
LT
D
1
KI
F2
1A
CO
L2
A1
FA
M
18
6A
CD
K4
PH
LD
A1
PT
PR
Q
UH
RF
1B
P1
L
UB
E3
B
O
AS
3
SB
NO
1
ST
AR
D
13
O
R4
M
1
R
EM
2
SP
TB
FO
XN
3
IT
PK
1
DY
N
C1
H1
TP
M
1
CS
K
H
D
G
FR
P3
EM
E2
TH
O
C6
TM
EM
21
9
TM
EM
21
9
IT
G
AM
AR
M
C5
D
N
AH
2
SC
O
1
O
SB
PL
7
PR
KC
A
PP
P4
R
1
H
O
O
K2
LE
N
G
9
C1
9o
rf1
8
PT
PR
A
M
X1
N
H
S
G
DP
D2
N
R
K
G
J A
5
C2
CD
4D
CL
K2
FZ
D
5
IF
T1
22
D
R
D
5
C6
or
f1
08
PK
H
D
1
RO
S1
R
B1
CC
1
BA
I1
AC
TN
3
D
IP
2B
N
SM
CE
1
KI
AA
05
56
KA
T2
A
LA
M
A3
LA
M
A3
H
O
M
ER
3
AN
KR
D
5
C2
0o
rf1
14
PR
R
14
L
EL
FN
2
TU
BG
CP
6
UB
E4
B
CO
L1
6A
1
C8
B
C1
or
f1
83
PA
R
P1
4
M
CC
C1
TM
EM
17
5
C4
or
f1
4
TE
T2
W
W
C2
M
FA
P3
EH
M
T2
AB
CC
10
TF
R
2
TN
KS
AC
O
1
PK
D
2L
1
N
PA
T
SR
PR
C1
2o
rf7
0
D
H
X3
8
FA
N
CA
N
LR
P1
AP
O
H
ZN
F5
41
M
AM
ST
R
M
ED
12
UN
C5
D
H
PX
PK
D
1
M
RT
O
4
DA
R
C
PT
PR
C
O
R2
W
5
AN
KR
D
23
N
PH
P1
G
PD
2
D
FN
B5
9
G
O
LG
B1
H
R
G
EN
C1
EL
L2
CP
EB
4
H
N
R
N
PA
B
CU
L9
KI
AA
19
19
M
YO
1G
TM
EM
20
9
KI
AA
01
46
AC
O
1
C9
or
f1
44
B
FA
M
10
7B
N
EB
L
DA
K
CD
3E
FM
N
L3
FA
M
18
6A
KS
R2
CD
H2
4
LR
R
1
KL
H
D
C2
FB
N
1
AN
P3
2A
AN
P3
2A
C1
6o
rf7
1
AP
O
BR
M
IN
K1
SL
C1
6A
11
SU
PT
6H
M
R
C2
TN
R
C6
C
FA
M
12
9C
CE
AC
AM
20
G
LT
SC
R1
FA
M
71
E2
ZN
F3
37
PP
EF
1
N
P1
P2
P3
M3
M4
M2
EH D
C L L L IQ C C1
9 FX
PF
A4 L
R
L5
O
R6
C
1
2
3
KI
AA
15
30
C4
or
f1
4
O
DZ
2
O
DZ
2
AD
AM
22
TM
EM
13
0
EH
BP
1L
1
D
CA
F1
1
CL
SP
N
PL
XD
C1
SL
C3
9A
1
IQ
GA
P3
CF
H
N
P1
P2
P3
M3
M4
M2
PP
D
PF
AP
EX
2
SL
C2
5A
43
F8 DN
AL
I1
UB
N2
R
YR
3
ZP
BP
2
G
NL
2
ET
V3
L
FC
RL
5
O
R6
K2
CO
PA
N
P1
P2
P3
M3
M4
M2
P3 (primary)
−1
0
1
1
2
3
4
0
0.5
1
Position (index)
2/1
M2 (pylorus)
−1
0
1
1
2
3
4
0
0.5
1
Position (index)
2/2
2/1
M3 (liver)
−1
0
1
1
2
3
4
0
0.5
1
Position (index)
BAF
CN
Log2
ratio
2/1
P3 (primary)
−1
0
1
1
2
3
4
0
0.5
1
Position (index)
3/2
M2 (pylorus)
−1
0
1
1
2
3
4
0
0.5
1
Position (index)
2/2
M3 (liver)
−1
0
1
1
2
3
4
0
0.5
1
Position (index)
BAF
CN
Log2
ratio
3/2
a
KI
AA
15
30
C4
or
f1
4
O
DZ
2
O
DZ
2
CA
F1
1
SP
N
XD
C1
C LS XCA
F1
1
D
C1
C3C LS LX L
b c d
e
f g h i
Figure 2 | Reversions in SNVs are explained by underlying CNAs. (a,f) ‘Early’ and ‘late’ tier-3 SNVs, respectively, which were predicted to be reversions in
the metastasis to the pylorus of patient 8/82. These were clustered on chromosome 1p and 17p. (b–d, g–i) Fully clonal somatic CNAs of chromosome 1 and
17, respectively, for the primary tumour, the pylorus and the liver metastases ordered according to their genomic coordinates. In each panel, the tracks
displayed are in descending order, the BAF, the integer based estimation of CN and the log2 ratios. (e) Heat map representing the ancestral state
reconstruction. The loss of heterozygosity at chromosome arm 1p and 17p in M2 explains the absence of these mutations.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14944
4 NATURE COMMUNICATIONS | 8:14944 | DOI: 10.1038/ncomms14944 |www.nature.com/naturecommunications
Common
ancestor
Metastatic
precursor
Ancestral
state
3*
b c
d
1 2 3 4 5
CD
C4
2B
PA
M
YD
88
CA
CN
A1
D
R
TP
1
M
O
G
KL
H
L3
2
KL
H
L3
2
FB
XL
4
IN
TS
1
KI
AA
19
67
PR
EX
2
FR
M
PD
2
H
KD
C1
LP
XN
BC
O
2
EF
CA
B4
B
A2
M
L1
SY
T1
0
LR
R
K2
SO
X2
1
SI
X4
ES
R2
SE
M
A7
A
CH
D3
PL
XD
C1
CD
30
0L
F
SP
O
11
M
IA
T
EL
FN
2
KC
ND
3
H
M
CN
1
FA
M
13
5B
PC
CA
TI
G
D7
PA
R
D
6G
TC
EB
3
O
TU
D7
B
R
PR
D
2
R
H
BG
O
R1
0K
1
KC
NJ
9
M
EI
S1
N
EB
BA
Z2
B
AL
S2
M
CM
2
PC
DH
G
A7
FR
K
H
YM
AI
W
D
R
72
R
N
F1
11
M
G
C1
29
16
PI
G
S
IG
F2
BP
1
D
SG
2
CA
CN
A1
A
ZN
F5
52
D
SC
AM
W
N
K3
EI
F2
C1
PO
G
Z
O
R2
W
5
M
ST
1
D
ER
L2
SL
C2
5A
13
Normal
P
M3
M2
M1
a
iv iii
viii i
i: Clonal and common to #1 and #2
ii: Clonal and private to #2
iii: Clonal and private to #1
iv: Subclonal and private to #1
v: Subclonal and private to #2
vi: Shared, clonal in #2 and 
subclonal in #1, incompatible with iii
vii: Shared, clonal in #1 and 
subclonal in #2, incompatible with ii
viii: Shared jointly sublconal
e
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
P
M
1
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
P
M
2
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
P
M
3
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
M1
M
2
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
M1
M
3
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
M2
M
3
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
#1
#2 v viii vii
2
13 4
2 25
3 4
5
1 1
4 5
1 3 4
2 5 2 4 5
1 3
2 5
1 3
3*
3*
3*
Truncal clonal Shared/private
clonal
Key 
Subclonal Absent
Normal breast
1
M1
(ovarium)
M2
(spleen)
M3 (lung)
P (primary
at surgery)
Common ancestor
Primary BC
ER-/PgR-/HER2-
2
3, 3* 4
5
Metastatic precursor
Whole-genome duplication
8q amp (MYC)
P (primary
at surgery) 
M1 (ovarium)
M2 (spleen)
M3 (lung) 
Figure 3 | Phylogenetic reconstruction of breast cancer progression in patient 7/67. (a) Ancestral state reconstruction of tier-3 SNVs with the anatomic
location of the proﬁled lesions is depicted in b. (c) Combined phylogenetic tree obtained from CNAs and SNVs and (d) pairwise comparisons of clonal
frequencies of tier-4 SNVs. The branches of the phylogenetic tree are labelled 1–5 and the location of these mutations in pairwise comparisons is indicated
in d. (e) Schematic representation of the pairwise comparison of two ﬁctitious samples. Mutations in i, ii and iii are fully clonal being either common to the
two samples and thus inherited from their parental lineage or private to either one. Mutations in iv and v are private and subclonal to either samples. They
are expected to have occurred after the divergence of the two lineages and after mutations located in ii and iii, respectively. Mutations in vi and vii are
shared between the two samples but are fully clonal in one and subclonal in the other. If the two samples share a common parental origin, these mutations
are incompatible with fully clonal mutations occurring in ii and iii, respectively. A possible scenario explaining their occurrence is that vi and vii are mutually
exclusive and that sample #1 seeded #2 giving rise to vi or vice versa for vii. The subclonal frequencies could then be explained by intra-tumour
heterogeneity in the tumour mass. Alternatively, mutations in vi and vii could ﬁnd their origin in horizontal reseeding from a third sample.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14944 ARTICLE
NATURE COMMUNICATIONS | 8:14944 |DOI: 10.1038/ncomms14944 |www.nature.com/naturecommunications 5
differ widely between early and advanced stage breast cancers,
it is imperative to determine in practice whether contralateral
tumours represent a metastatic deposit of the primary tumour.
Evolution of genomic alterations during cancer progression.
We computed for each lesion, a normalized phylogenetic branch
length, which is the ratio of the path from the common ancestor to
the given lesion relative to the common trunk (Fig. 6a,b). This
represents the extent of genomic alterations that accumulated since
the ﬁrst metastasizing event took place irrespective of the mode of
progression. With few exceptions, the pattern observed from tier-3
SNVs mirrors the one from CNAs. In patients 1/69, 2/57 and 4/71,
who all died from their disease at most 1 year after initial diagnosis,
the bulk of evolutionary changes occurred ‘early’ in the trunk of the
phylogenetic tree. At the other extreme, in patients 8/82, 9/68 and
10/80, who had a longer disease history, the SNV proﬁle is unco-
ordinated with the CNA whereby the former shows that most of
the evolutionary changes occurred ‘late’. Figure 6c,d shows the
correlation of the average normalized phylogenetic branch lengths
with overall survival. Although the number of patients is small, we
observed a positive correlation for both CNAs and SNVs.
In patients 8/82 and 10/80, we observed a high mutational
burden which showed evidence of increased C4T substitutions
at NpCpG trinucleotides. This pattern of substitution is
reminiscent of mutational signature 13 in Alexandrov et al.24
Figure 7a,b shows the pattern of substitutions observed in the
trunk, that is, ‘early’, and in branches, that is, ‘late’, during
the evolutionary cascade of these two patients. Thus, it is
possible that, in at least these two patients, the activation of the
APOBEC family of cytidine deaminases caused an accumulation
of mutations which uncoupled the SNV and CNA proﬁles.
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Patient 10/80 harboured an ‘early’ ampliﬁcation of the APOBEC
cluster on chromosome 22 (Supplementary Data 4) while patient
8/82 harboured an ‘early’ APOBEC3B D316N mutation
(Supplementary Data 3).
Discussion
Herein, we applied phylogenetic techniques to infer the
evolutionary history of breast cancer progression from an autopsy
cohort of ten patients. In contrast to previous reports, which
compared single metastasis and primary tumour pairs only or
multiple-matched metastases and primary tumours for no more
than two patients, the availability of a larger number of patients
with matched primary and multiple metastatic samples was
critical to our study for deciphering the routes of dissemination
underlying metastatic progression.
We observed two possible scenarios. The most frequent
implied a single successful seeding event from the primary
tumour followed by metastasis-to-metastasis cascading dissemi-
nations, whereas the second involved multiple seeding events
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from the primary tumour alongside daughter metastasis-to-
metastasis disseminations. This dichotomy coincides with the
clinical history where, except for patient 5/87, descent from
a common metastatic origin was observed in patients diagnosed
with early stage breast cancer, whereas multiple seeding
events from the primary tumour occurred in patients diagnosed
with advanced stage disease.
The role of primary tumour resection in de novo metastatic
breast cancer patients is unclear, and there is currently no
consensus whether this procedure confers a survival beneﬁt.
A recent open label trial did not support primary surgery
in de novo metastatic patients progressing to front-line
chemotherapy25 and in a subgroup analysis of a Turkish
study26, patients with multiple liver and lung metastases did
worse in the primary surgery group consistent with earlier reports
that surgical excision of the primary tumour might enhance the
growth of micrometastases27–29. However, in the same trial by
Soran et al.26, the authors observed an increased progression free
survival for primary tumour resection in ERþ /HER2-de novo
metastatic patients with solitary bone metastases. Thus, our
observations suggest that surgical excision of the primary tumour
might reduce metastatic dissemination in selected cases hence
providing a potential biological rationale for this practice.
Similarly, there is no strong recommendation showing overall
survival beneﬁt from surgical resection of oligo-metastases in
breast cancer. From our analyses, metastatic lesions constitute an
additional source of seeding and heterogeneity in advanced breast
cancer. Our cohort is too small to derive practice-changing
evidence, but supports the concept that resecting isolated
metastases may be of clinical beneﬁt in oligo-metastatic breast
cancer patients. In both cases, results from larger, prospective
studies are warranted.
We reckoned that the number of ‘late’ SNVs and CNAs, should
increase as distant metastases evolve and should give an
indication, albeit approximate, of the time elapsed since they
last diverged from their common ancestor. Indeed, we observed
a positive correlation between overall survival and the
average normalized phylogenetic branch lengths. This can be
explained by the fact that patients 1/69 and 2/57 were de novo
metastatic and consistent with those two patients, 4/71 also had
a very short distant metastasis free and overall survival. At the
other extreme, in patients 8/82, 9/68 and 10/80 who relapsed
more than 4 years after initial diagnosis, the extent of ‘late’
genomic alterations were commensurate with the survival of
the patients. These results suggest, not unexpectedly, that
metastases from patients with longer cancer histories are
genetically more distant from their ‘common ancestor’ or their
primary tissue of origin than those of patients with a shorter
cancer history.
Evidence has been accumulating in the literature regarding
treatment-induced genomic remodelling15,16,30–37, especially
implicating ESR1 and PTEN alterations in endocrine and
PI3K-inhibitor resistance, respectively. In our series, four out of
the ﬁve ER-positive patients received aromatase inhibitors.
However, no ESR1 mutations have been detected in their
distant metastases. None of the patients received any
PI3K-inhibitor making it impossible to evaluate resistance
mechanisms associated to this treatment.
Overall, by characterizing the genomic alterations that shape
metastatic genomes, we have gleaned new insights into the
dissemination patterns of breast cancer with potential clinical
implications: (1) cascading dissemination from metastases
appears to be a major route of metastatic progression in early,
radically resected breast cancer and (2) primary tumours at
diagnosis may not adequately represent advanced metastatic
disease advocating the need for genetic characterization of
multiple metastatic lesions. The very recent technical advances
in the assessment of circulating tumour DNA38 may both allow
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the early detection of micrometastatic disease before recurrence
and may better capture tumour heterogeneity of metastatic
disease guiding the best therapeutic options for early and
advanced breast cancer patients in the future. Genomic
alterations uniquely deﬁning breast cancer metastases from an
aetiological standpoint, and therapeutic agents tackling them
are yet to be found.
Methods
Patients and samples. The average period between the time of death and
acquisition of autopsy samples was 2.8 days (1.5–4.2). Between the time of death
and dissection, the cadavers were kept at 4 C. At autopsy, complete external and
detailed internal examinations were performed. The organs were thoroughly
examined, weighed and tissue samples were taken. All tissue samples were ﬁxed in
formalin and embedded in parafﬁn as part of routine workup. All bone samples
were decalciﬁed using EDTA solution to preserve the antigenicity of the tissue
proteins. Hematoxylin-eosin (HE) stained sections were reviewed by J.K., A.M.S.
and B.S. to conﬁrm the presence and percentage of invasive carcinoma as well
as other tissue composition. A detailed description of the clinico-pathological
characteristics of each patient is provided in Supplementary Data 1. This project
was approved by the Institutional Review Board (IKEB 185-1/2007). This study
is retrospective in nature and part of a larger institutional-based autopsy pro-
gramme carried out at the Semmelweis University. It did not impact treatment
decision for the patients involved and received approval from the ethical committee
of the Semmelweis University.
Pathological characterization of samples. The stage of primary tumours
was reclassiﬁed based on the 7th version of TNM classiﬁcation system.
Immunohistochemistry (IHC) and ﬂuorescence in situ hybridization (FISH) were
performed on 4 mm tissue sections. All the samples underwent centralized IHC
for the oestrogen (ER) and progesterone (PgR) receptor status and IHC/FISH
characterization for HER2 receptor status. Hormone receptor and HER2 status
were assessed by IHC on all samples with an automated immunostainer system
(Ventana Benchmark, Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s instructions with the following antibodies: ER–SP1 rabbit
monoclonal (Ventana #790-4324) ready to use kit, PgR–1E2 rabbit monoclonal
(Ventana #790-2223) ready to use kit, Ki-67–MIB1 (DAKO #M7240, Carpinteria,
CA, USA) at dilution 1:100 and HER2/neu–4B5 (Ventana #800-2996) ready to use
kit. Hormone receptor status was evaluated using Allred-Quick scoring system by
two investigators independently (A.M.S. and B.S.). Ki-67 index was measured
as the ratio of the positive tumour cell nuclei in the sample. IHC assessment of
Ki-67 was evaluated only on the primary tumours. HER2 positivity was primarily
deﬁned at protein level using IHC and supplemented by FISH using Poseidon
probes (Kreatech Diagnostics, #KBI-10735, Amsterdam, Netherlands). HER2
IHC was evaluated according to the modiﬁed standard protocol that is, positive by
IHC only if more than 30% of tumour cells show strong, complete membrane
reaction. FISH was performed on samples with IHC 2þ and 3þ for the
evaluation of HER2 gene ampliﬁcation status. FISH results were evaluated
according to the 2013 ASCO/CAP guidelines39. A detailed review of all
samples is provided in Supplementary Data 2.
DNA isolation. DNA was extracted from the primary tumours, metastases and
matched normal tissue from FFPE tissue blocks after macrodissection using
the QIAamp DNA FFPE Tissue Kit (Qiagen, #56404, Hilden, Germany).
Double-stranded DNA (dsDNA) was quantiﬁed using the QUBIT 2.0 Fluorometer
(Invitrogen) and the PicoGreen assay for double-stranded DNA. Only samples
from which41 mg of double-stranded DNA, as quantiﬁed by the two assays could
be extracted, were selected for downstream molecular proﬁling.
Exome and targeted sequencing analysis. For each patient, part of the available
samples was used to index the presence of SNVs using whole-exome sequencing.
A total of 51 samples including at least one normal sample per patient were
sequenced at a target coverage of 40 . The putative somatic SNVs were validated
by Sequenom MassARRAY in both the germline reference and cancer samples.
As further validation, all available cancer samples were subjected to targeted
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Figure 7 | Distribution of substitutions during metastatic progression. Frequency of the different types of substitutions for tier-3 SNVs in patients
(a) 8/82 and (b) 10/80. These are grouped as ‘early’ and ‘late’ according to their occurrence in the respective phylogenetic trees.
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amplicon deep sequencing at a median coverage of 9,000 to conﬁrm initial
sequencing results and increase the accuracy of VAFs.
Whole-exome DNA libraries were generated following the manufacturer’s
protocol with minor modiﬁcations (Illumina TrusSeq DNA library preparation kit
v2). Before end-repair, a 65 C incubation step was added to remove reversible
crosslinks, after which excessive single-stranded DNA was removed enzymatically.
The concentration of double-stranded DNA was assessed using the PicoGreen
assay and the concentration of adapters used for ligation was adjusted accordingly.
For the library enrichment, 5–7 cycles of PCR were used. Whole-exome capture
was then performed using the Illumina Human Exome capture kit and libraries
were sequenced on a HiSeq2000 using V3 ﬂowcells generating 2 100 bp
paired-end reads. Raw sequencing reads were mapped to the human reference
genome (NCBI37/hg19) using the Burrows-Wheeler Aligner (BWA)40 and aligned
reads were processed with SAMtools41. Duplicate reads were removed using Picard
tools. Base recalibration, local realignment around indels and SNV calling were
performed using the GenomeAnalysisToolKit (GATK)42. Indels were called
using Dindel43. Mutations were ﬁltered based on mapping quality, and sequencing
coverage. Somatic mutations were further ﬁltered by comparison with the matched
germline reference and using common variant databases such as the 1000 genomes
project44 and dbSNP version 132 (ref. 45).
For the targeted resequencing experiments, primers were designed using the
Sequenom’s MassARRAY assay design software and universal sequence tags were
added manually. Amplicons encompassing the mutation of interest were generated
using a ﬁrst PCR (Roche FastStart High Fidelity PCR kit) with universal sequencing
adapters (Access Array Barcode) containing a 10 bp index added in a second PCR.
The resulting PCR products were pooled, denatured and sequenced on an Illumina
MiSeq in a 2 75 bp paired-end sequencing run using a V3 ﬂowcell. Fastq ﬁles
were generated and demultiplexed using CASAVA. The raw sequencing reads were
mapped to the human reference genome (NCBI37/hg19) using BWA. Read counts
of both variant and reference alleles were called using GATK and manually checked
in IGV46.
Tiering system for ﬁltering SNVs. A ﬁve-tier system was devised to ﬁlter SNVs
for downstream analysis (Supplementary Data 3). We considered tier-0 SNVs as
any SNV indexed in any sample including the matched germline reference by
exome sequencing. Tier-1 SNVs are those that were further called somatic after
comparison with the germline reference while tier-2 SNVs are the subset of
tier-1 which have been further validated and conﬁrmed somatic by Sequenom
MassARRAY. Tier-3 SNVs are the further subset that was conﬁrmed present by
targeted deep amplicon sequencing. Due to formalin ﬁxation and parafﬁn
embedding, at some loci, all four bases were often observed at low frequencies.
Thus, to determine the background noise of the targeted deep sequencing
experiments, we selected 25 bp upstream and downstream of tier-2 SNVs. For
each position, the number of reads for the reference nucleotide and the other
3 non-reference nucleotides was determined using GATK. To exclude possible
SNPs or SNVs other than the one of interest, we removed all data points that
showed more than 10% non-reference reads. We then pooled all the data for each
mutation type (AT4CG, AT4GC, AT4TA, CG4AT, CG4GC and CG4TA)
and calculated the average background signal and s.d. From these estimates, the
highest value observed was 1.59%. Thus, we chose a conservative value of 3% as the
ﬁnal cut-off for calling a mutation present.
In the present context, several samples were matched to a given patient and we
found it equally important to have a high coverage to call a mutation present in one
sample, as it is to call absence in another paired sample. Thus, at the tier-3 level, we
ﬁrst ﬁltered all SNVs in all matched samples to have a coverage of 41,500 and
kept samples with a minimum of 75% non-missing values. We then excluded all
SNVs with 41 missing value across any of the matched samples previously
retained. We reversed the ﬁltering order for VAFs by ﬁrst eliminating SNVs that
were called absento3% across all matched samples previously retained. Because of
low CCF, it is likely that some samples have a lower total number of SNVs called
present. However, a lower number of detected mutations could also be biologically
grounded. Therefore, we use a lenient ﬁltering to exclude samples with potentially
low CCFs by requiring that 420% of SNVs be called present. Some samples
showed a large number of SNVs or had limited starting DNA available. For those
samples, we were compelled to skip validation by Sequenom MassARRAY and thus
the tier-2 level. Finally, we required that for all samples where a matched-SNP
array and targeted sequencing were available, that the sample displays
a CCF 430% as determined by SNP array. All SNVs from that sample were
then referred to as tier-4 SNVs
SNP array analysis. For the estimation of CNAs, a total of 64 samples were
shipped for processing to the Affymetrix Research Services Laboratory. Normal
and tumour DNA from FFPE samples were genotyped using the Affymetrix
OncoScan FFPE Express 2.0 arrays. Routine formalin ﬁxation and parafﬁn
embedding frequently damages DNA causing wavy proﬁles, which may be wrongly
interpreted as copy number aberrations. Thus, the median absolute pairwise
deviation (MAPD) and the median auto-correlation (MAC) across the log2 ratio
intensities were used as quality control for the SNP arrays (Supplementary Data 2).
Samples with an MAPD40.7 or an MAC40.3 were discarded. Samples suspected
to have a low CCF on visual inspection of the BAF tracks were ﬂagged and after
processing, those conﬁrmed to have less than 30% CCF were discarded from
downstream applications. From the remaining samples, only informative probes
displaying heterozygous genotype (AB) and copy-neutral state (2) in the
matched normal sample were kept for analysis. We used the added value of
multiple-matched samples per patient to infer breakpoints, which may otherwise
have been missed due to differences in CCF across the various samples. The
log2 ratio intensities and BAF, grouped per patient, were segmented jointly using
the multitrack PCF algorithm in the R package copynumber47 to determine
common breakpoints. The penalty parameter g determining discontinuities in the
log2 ratio and BAF tracks was set individually for each patient after visual
inspection of the segmentation proﬁles. Finally, all segments that were less than
three s.d. away were merged with their immediate neighbours.
Integer level estimates of total copy number and major allele were obtained
using GAP48. We compared the estimates returned by GAP with two other
mainstream programs: (1) ASCAT49 and (2) ABSOLUTE21. Unless otherwise
stated, the parameter sets for each programme were kept at default values. For
ASCAT, the parameter g, which determines the platform-speciﬁc compression
ratio, was set to 0.8. The programme returns one default estimate of ploidy and
CCF, which was used in the comparison against GAP. ABSOLUTE was run in
‘total copy’ mode and model based evaluation against the SNP6 platform. The
fraction of the genome allowed to be non-clonal was set to inﬁnity so that the
maximum number of solutions could be evaluated. ABSOLUTE returns a set of
possible values for ploidy and CCF. The closest solution to that returned by GAP in
Euclidean space, after rescaling ploidy values to unit distance, was chosen. The
results obtained by GAP, ASCAT and ABSOLUTE are contrasted in
Supplementary Fig. 10a,b. In all three cases, the Spearman’s r between the
estimated CCF was high. In the case of ploidy estimates, the correlation between
GAP and ASCAT was relatively low due to two reasons: (1) several matched
samples from two patients displayed ploidy values outside the range considered by
ASCAT and (2) at several loci displaying high copy numbers, GAP truncates the
estimate to 8 while ASCAT does not thereby affecting the true estimate. We
computed the Cohen’s k coefﬁcient between ASCAT and GAP to measure the
agreement in total copy numbers and major alleles. These are displayed in
Supplementary Fig. 10c while the correlation of the k coefﬁcients for total copy
numbers and the absolute difference in ploidy between the two algorithms is shown
in panel d. The results showed that the disagreement between the two programs in
the phasing of alleles and estimation of total copy numbers is in fact linked to the
discordances in ploidy (r¼  0.898, Po0.01). Because the present dataset
contained matched samples and may represent a biased result, we used an
additional dataset of 125 unrelated samples proﬁled using similar Affymetrix
OncoScan SNP arrays (unpublished data) to reproduce the analysis. Supplementary
Figure 11a,b shows a very good correlation between the two estimates of ploidy
(r¼ 0.885, Po0.01) and CCF (r¼ 0.907, Po0.01). However, the correlation of the
k coefﬁcients for total copy numbers and the absolute difference in ploidy
(r¼  0.733, Po0.01) or CCF (r¼  0.119, P¼ 0.147) shows that it is, in fact,
the incorrect estimation of global genomic mass that leads to disagreement between
the two algorithms. Supplementary Figure 11f–m contrasts the results from
GAP and ASCAT for four samples with increasing genomic mass and illustrates
the complexity of choosing the correct solution of CCF and ploidy. Given the
present context of matched samples and because GAP allowed for manual review
of ploidy solutions, we opted for this package for downstream analyses taking into
consideration the maximal limit of eight copies imposed by the software as follows:
(1) SNVs that occurred at loci where the total copy number was 8 or a major allele
count 44 was observed were not considered for the estimation of CCF or clonal
frequency and (2) similarly for the phylogenetic reconstructions using CNAs,
except in the case of high ploidy tumours (that is, 1/69, 7/67, 8/82 and 10/80) any
locus displaying a total copy number of 8 or a major allele count44 in any sample
was removed from all matching samples of that particular patient.
Estimation of CCF and clonal frequencies from tier-4 SNVs. The CCF was
estimated both individually from each tier-4 SNV and globally from the whole set
of tier-4 SNVs in samples where a matched-SNP array was available. Let qt denote
the total copy number at the mutated locus, q1 denote the minor copy number and
q2 denote the major copy number such that q2Zq1, qt¼ q1þ q2 and q1, q2 and
qtAa . Let sq denote the number of mutated copies such that sqA{1,y, q2}.
Let fsq denotes the expected VAF of the SNV where fsqA[0,1]. Then, fsq is related
to sq and a, the CCF, as follows:
fsq ¼ sq aaqt þ 2ð1 aÞ
 
ð1Þ
where a is the variable that we are trying to estimate while f^ is taken to be
the observed VAF. We denote the estimate of CCF from sequencing as a^. The
above equation can be rearranged such that
a^ ¼ 2f^
sq  f^ ðqt  2Þ
ð2Þ
Let n be the total number of sequencing reads that cover the mutated locus. Then
Pr X nf^
 
¼ osqBeta fsq nf^ þ 1; nð1 f^ Þþ 1
  ð3Þ
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where X is the number of mutated reads for a given SNV, wsq specify the mixture
weights for each possible value of sq. Computation of fsq requires prior knowledge
of a. To estimate sq and for individual SNVs irrespective of other mutations, we
make the assumption that a is known. Thus, qt, q1, q2 and a are plugin quantities
obtained from the corresponding SNP array. Then
sq ¼ argmax
sq2f1; ... ;q2g
PrðX ¼ nf^ Þ
n o
ð4Þ
and the sequencing error eA[0,1) is modelled after Purdom et al.50 such that
fe ¼ 13 2e ð3 4eÞfsqþ e
  ð5Þ
replaces fsq in the Beta distribution. We use uniform priors over the range of
possible values of sq and e¼ 0.01. These form the basis of the pointwise estimates
of CCFs (Supplementary Fig. 10b). To relax the requirement on prior knowledge
of a, we deﬁne the likelihood function over all tier-4 SNVs present in a given
sample as
L f n; sq;osq
  ¼ X
sq2f1; ... ;q2g
Pr X nf^
 
ð6Þ
At a given value of a, we compute the log of L and iteratively adjust the weights
wsq until L converges or a maximum of 100 iterations is reached. The global CCF,
a , is the value that maximizes L such that
a ¼ argmax
a2f0:1; ... ;0:9g
Lðf^ aj Þ
n o
ð7Þ
An example is shown in Supplementary Fig. 10e–f and a is compared to the
estimate of GAP in Supplementary Fig. 10g. The CCF and the clonal frequency
of SNVs are related and the latter was computed jointly for all samples belonging
to a given patient using PyClone51 from the estimates of major and minor copy
numbers returned by GAP. We used a Beta Binomial distribution with parental
copy number option and default parameter settings except for the sequencing
error which was set to 0.01 and the tumour content which was set to the global
CCF, a , estimated above.
Phylogenetic analysis of SNVs. The raw VAFs of tier-3 SNVs from targeted
resequencing were converted into binary calls based on a threshold of 3%. We
initially intended to ﬁlter in only fully clonal tier-3 SNVs using this conservative
cut-off and infer the phylogeny for individual patients using the Dollo parsimony
method and a branch and bound exhaustive search for the best phylogenetic
reconstruction as described in Felsenstein52 using the programme PHYLIP. The
outgroup used for rooting the phylogenies was one where all the characters were set
to the ancestral state 0. The Dollo parsimony criterion minimizes homoplasies at
the expense of reversions in later branches and the criteria for determining the best
phylogenetic tree is minimizing the number of such reversions. Despite this, several
phylogenetic trees can be equally parsimonious. Instead of collapsing the trees
using consensus methods, we used the corresponding CNA based tree to break ties
and infer the correct phylogeny. The trees in Newick format were rendered using
the R package ape53. The heat maps representing the tier-3 SNVs were ordered
according to the topology and branch lengths of their corresponding phylogenetic
trees via an ancestral state reconstruction using the accelerated transition
model54,55 as provided in the R package phangorn56. The phylogenetic trees for
each patient are shown in Supplementary Fig. 7. Each predicted reversion of
SNV was manually veriﬁed against the underlying CNA proﬁle. The tier-3 level
does not take into account the CCF of the samples. It is possible that, despite the
previous ﬁlters, very low CCF samples with overall fewer positive mutation calls are
included. These samples would lead to early branches in the trunk of the
phylogenies. Thus, we reproduced the same analysis with samples having tier-4
SNVs. The results are shown in Supplementary Fig. 8.
Phylogenetic analysis of CNAs. The major and minor copy numbers returned by
GAP were modelled using a transducer-based pairwise comparison function using
the programme MEDICC57. For near-diploid samples, we assume a pure diploid
outgroup with no copy number aberrations that is, 2/1 (total copy number/major
allele) to root the phylogenies. In the case of tetraploid samples, we included an
additional step to phase CNAs relative to the whole-genome duplication event
within the phylogeny of the given patient. We ﬁrst used the classic approach to
infer an intermediate tree with correct topology irrespective of branch lengths. For
the major or minor copy and at each locus, we compute a parsimony score, which
is the sum of branch lengths of the intermediate tree rooted using any of the four
tetraploid ancestral states 6/4, 4/2, 4/4 and 2/2 (total copy number/major allele).
These represent the copy number states 3/2, 2/1, 2/2 and 1/1 following
a whole-genome duplication event. We used all possible permutations of observed
copy numbers at the internal nodes except for 0-1 transitions. We chose the
intermediate tree and thus the related tetraploid ancestral state obtaining the
minimum score. Ties, if present, are broken by summing the intermediate
tree length with the CNAs occurring prior to the whole-genome duplication that
is, 1, 0, 2 and 1, respectively. Finally, the global phylogenetic tree is inferred using
the classic approach jointly at all loci and rooted using the tetraploid ancestor as
outgroup. The phylogenetic trees are shown in Figs 3–5 of the main text and
Supplementary Fig. 9. Support values for the phylogenetic trees were obtained
by resampling the pairwise distance matrix 100 times with added Gaussian noise
and counting similar bipartitions between the resulting trees and the original
phylogeny.
Data availability. The sequencing and SNP array data have been deposited at the
European Genome-Phenome Archive (http://www.ebi.ac.uk/ega/), which is hosted
by the European Bioinformatics Institute, under accession number
EGAS00001000760.
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